Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17227610 | 0.85 | LMNA (0.61) | SMN1; SMN2LMNAALDH1A1PKMHPGD | |
| SCHEMBL27182624 | 0.84 | LMNA (0.60) | SMN1; SMN2LMNAALDH1A1PKMHPGD | |
| SCHEMBL30872951 | 0.84 | LMNA (0.60) | SMN1; SMN2LMNAALDH1A1PKMHPGD | |
| Cyanide SCHEMBL28184916 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAALDH1A1PKMHPGD | |
| SCHEMBL6526296 | 0.81 | CYSLTR2 (0.58) | SMN1; SMN2LMNAALDH1A1PKMHPGD | |
| SCHEMBL10294171 | 0.81 | SLC22A12 (0.46) | SMN1; SMN2LMNAALDH1A1PKMHPGD | |
| SCHEMBL28000117 | 0.80 | SLC22A12 (0.58) | ALDH1A1HPGDALOX15HTTBRD4 | |
| SCHEMBL6086574 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAALDH1A1PKMHPGD | |
| SCHEMBL10751084 | 0.79 | AR (0.54) | LMNAARKMT2ARAB9AMEN1 | |
| SCHEMBL11518974 | 0.78 | SYK (0.57) | SMN1; SMN2LMNAALDH1A1PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | SMN1; SMN2 1130/4885LMNA 4235/4885ALDH1A1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.